Clinical trial · no report yet · Phase 3
IMbrave251
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- NCT04770896 ↗
- Active not recruiting
- Hoffmann-La Roche
- 37 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| Podcasts | 10 | |
| YouTube | 9 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- Atezolizumab; Lenvatinib; Sorafenib
- Arms
- Atezolizumab + Lenvatinib or Sorafenib · Experimental
- Lenvatinib or Sorafenib · Active comparator
- Enrollment
- 557
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Hoffmann-La Roche
- Start
- Apr 26, 2021
- Primary completion
- Oct 14, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04770896 · updated Aug 25, 2026